Tech Company Financing Transactions
BridgeBio Pharma Funding Round
KKR, Viking Global Investors and Aisling Capital joined a $299.2 million funding round for BridgeBio Pharma. This venture round closed on 1/24/2019.
Transaction Overview
Company Name
Announced On
1/24/2019
Transaction Type
Venture Equity
Amount
$299,200,000
Round
Undisclosed
Investors
Proceeds Purpose
The financing will be used to support BridgeBio Pharma's existing drug research and development programs and expand its efforts to rapidly develop medicines for patients with unmet needs.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
421 Kipling St.
Palo Alto, CA 94301
USA
Palo Alto, CA 94301
USA
Phone
Website
Email Address
Overview
BridgeBio Pharma (Nasdaq: BBIO) is a collection of individuals focused on discovering and developing drugs for patients with grievous genetic diseases.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Neil Kumar
Browse more venture capital transactions:
Prev: 1/24/2019: Liquid Instruments venture capital transaction
Next: 1/24/2019: Confluent venture capital transaction
Share this article
About Our Venture Capital Transactions Database
We do our best to document funding rounds that are announced publicly. VC investment data records reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs